Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,707 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,707 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Enrollment posture brief
Registry condition hiv-infections
OPEN 56 | RECR 9% | LATE 92 | EARLY 266 | RANK #7 | SPON 195
Volume-matched condition peers
Nearest open-share peer: Acute Lung Injury (9% recruiting · 11 trials)
HIV Infections lists 56 open slots (9% of 615 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 2 of 13
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06665646
Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)
University of Miami
NCT06730555
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
Brigham and Women's Hospital
NCT05378399
Imaging Immune Activation in HIV by PET-MR
CellSight Technologies
NCT03684655
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
ViiV Healthcare
NCT05674656
CAR-T Cells for HIV Infection
Steven Deeks
NCT04648046
Consent for Use of Stored Patient Specimens for Future Testing
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT00031408
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
ViiV Healthcare
NCT03299049
Cross-disciplinary HIV Integrated Mental Health Support Intervention
Emory University
NCT04833829
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
ViiV Healthcare
NCT02938520
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ViiV Healthcare
NCT02951052
Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence
Ann & Robert H Lurie Children's Hospital of Chicago
NCT05783297
Expanding the Potential of Couples HIV Testing: Adjunct Modules to Reduce Drug Use Among Vulnerable Male Couples
Hunter College of City University of New York
NCT05000866
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
Emory University
NCT06205368
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03635788
Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care
Johns Hopkins University
NCT04601064
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
ViiV Healthcare
NCT02362503
Entre Herman@s: Promoting Health Among Latino MSM
Charles Drew University of Medicine and Science
NCT05805306
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ViiV Healthcare
NCT06741397
Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV
Seattle Institute for Biomedical and Clinical Research
NCT04505371
Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs
Drexel University
NCT05192434
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ViiV Healthcare
NCT05911360
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ViiV Healthcare
NCT05996471
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
Janssen Sciences Ireland UC
NCT00980538
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
ViiV Healthcare
NCT05917509
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
Theratechnologies
NCT05388474
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV
Gilead Sciences
NCT02016924
Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: a Cardiac MRI Study
Massachusetts General Hospital
NCT03238755
A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05217641
A Simple Intervention to Increase Persistence on PrEP in MSM to Improve Decision Making
Boston University
NCT06476847
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
ViiV Healthcare
NCT06652958
Mobilizing Social Network Resources for HIV Care Support
Medical College of Wisconsin
NCT05123274
Tele-Harm Reduction
University of Miami
NCT05208697
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
VA Eastern Colorado Health Care System
NCT03729778
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults
ViiV Healthcare
NCT06012136
Trauma-informed Care for Youth With HIV in Memphis
Meharry Medical College
NCT07137026
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
NCT06316739
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults
ViiV Healthcare
NCT06786520
A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV
ViiV Healthcare
NCT06970223
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06557785
The Cheeky Study: A Novel Delivery System for CAB-RPV LA
Public Health Foundation Enterprises
NCT05979714
A Systems Analysis and Improvement Approach for Optimizing HIV Service Delivery in Syringe Services Programs
University of California, San Diego
NCT06025435
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05551273
Evaluation of Neuroinflammation FNOS PET/CT in HIV (+) and (-) Subjects With OUD and Healthy Controls
University of Pennsylvania
NCT04401917
Buprenorphine Integration Research and Community Health
Yale University
NCT05668780
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT07182838
Clinical Decision Support for PrEP
Harvard Pilgrim Health Care
NCT05245201
A Study of Patients With AIDS Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001120
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
The Immune Response Corporation
NCT00002359
Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test
Chembio Diagnostic Systems
NCT01032902
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV Infections page
615 registered trials, 56 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 56 HIV Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV Infections trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV Infections condition card totals 615 registered trials; most-linked intervention Zidovudine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.